81 related articles for article (PubMed ID: 28030635)
1. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value.
Rosager AM; Sørensen MD; Dahlrot RH; Hansen S; Schonberg DL; Rich JN; Lathia JD; Kristensen BW
PLoS One; 2017; 12(8):e0182954. PubMed ID: 28837569
[TBL] [Abstract][Full Text] [Related]
2. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognostic value of JAM-A in gliomas.
Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
[TBL] [Abstract][Full Text] [Related]
4. Complement activation in astrocytomas: deposition of C4d and patient outcome.
Mäkelä K; Helén P; Haapasalo H; Paavonen T
BMC Cancer; 2012 Dec; 12():565. PubMed ID: 23199209
[TBL] [Abstract][Full Text] [Related]
5. Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights.
Crespin S; Fromont G; Wager M; Levillain P; Cronier L; Monvoisin A; Defamie N; Mesnil M
Cancer Med; 2016 Aug; 5(8):1742-52. PubMed ID: 27306693
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients.
Adam SA; Schnell O; Pöschl J; Eigenbrod S; Kretzschmar HA; Tonn JC; Schüller U
Brain Pathol; 2012 Nov; 22(6):788-97. PubMed ID: 22417385
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen and progesterone receptors in astrocytomas: a literature review.
Tavares CB; Gomes-Braga Fd; Costa-Silva DR; Escórcio-Dourado CS; Borges US; Conde-Junior AM; Barros-Oliveira Mda C; Sousa EB; Barros Lda R; Martins LM; Facina G; da-Silva BB
Clinics (Sao Paulo); 2016 Aug; 71(8):481-6. PubMed ID: 27626480
[TBL] [Abstract][Full Text] [Related]
8. Proteomics reveals differentially regulated pathways when comparing grade 2 and 4 astrocytomas.
Verissimo DCA; Camillo-Andrade AC; Santos MDM; Sprengel SL; Zanine SC; Borba LAB; Carvalho PC; da G Fischer JS
PLoS One; 2023; 18(11):e0290087. PubMed ID: 37967105
[TBL] [Abstract][Full Text] [Related]
9. Brain tumor classification using AFM in combination with data mining techniques.
Huml M; Silye R; Zauner G; Hutterer S; Schilcher K
Biomed Res Int; 2013; 2013():176519. PubMed ID: 24062997
[TBL] [Abstract][Full Text] [Related]
10.
Volnitskiy A; Shabalin K; Pantina R; Varfolomeeva E; Kovalev R; Burdakov V; Emelianova S; Garaeva L; Yakimov A; Sogoyan M; Filatov M; Konevega AL; Shtam T
Curr Issues Mol Biol; 2024 Jan; 46(2):1107-1120. PubMed ID: 38392188
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates.
Li Q; Aishwarya S; Li JP; Pan DX; Shi JP
Front Genet; 2022; 13():832742. PubMed ID: 35571016
[TBL] [Abstract][Full Text] [Related]
12. Differences in stem cell marker and osteopontin expression in primary and recurrent glioblastoma.
Polat B; Wohlleben G; Kosmala R; Lisowski D; Mantel F; Lewitzki V; Löhr M; Blum R; Herud P; Flentje M; Monoranu CM
Cancer Cell Int; 2022 Feb; 22(1):87. PubMed ID: 35183162
[TBL] [Abstract][Full Text] [Related]
13. In silico identification of natural product inhibitors against Octamer-binding transcription factor 4 (Oct4) to impede the mechanism of glioma stem cells.
Nayak C; Singh SK
PLoS One; 2021; 16(10):e0255803. PubMed ID: 34613998
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.
Ma T; Hu C; Lal B; Zhou W; Ma Y; Ying M; Prinos P; Quiñones-Hinojosa A; Lim M; Laterra J; Li Y
Cancer Res; 2021 May; 81(9):2457-2469. PubMed ID: 33574085
[TBL] [Abstract][Full Text] [Related]
15. THE EXPRESSION OF STEM CELL MARKERS (CD133, NESTIN, OCT4, SOX2) IN INVASIVE PITUITARY ADENOMAS.
Basaran R; Gundogan D; Senol M; Bozdogan C; Gezen F; Sav A
Acta Endocrinol (Buchar); 2020; 16(3):303-310. PubMed ID: 33363651
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis.
Zhao X; Lu H; Sun Y; Liu L; Wang H
Medicine (Baltimore); 2020 Oct; 99(42):e22804. PubMed ID: 33080755
[TBL] [Abstract][Full Text] [Related]
17. Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer.
Hassn Mesrati M; Behrooz AB; Y Abuhamad A; Syahir A
Cells; 2020 May; 9(5):. PubMed ID: 32429463
[TBL] [Abstract][Full Text] [Related]
18. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
Musah-Eroje A; Watson S
J Neurooncol; 2019 Apr; 142(2):231-240. PubMed ID: 30694423
[TBL] [Abstract][Full Text] [Related]
19. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
